The present invention is directed to a new kind of medicinal value or health care function of Eurycoma longifolia extracts, particularly in the treatment or alleviation symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. In one aspect, the present invention discloses the use of a composition comprising a therapeutically effective amount of Eurycoma longifolia extract in the manufacture of a medicament for the alleviation of symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. The alleviation of the symptoms and/or conditions according to the present invention is characterised by inducing a change in the hormonal contents of estrogen, progesterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Also disclosed is the use of a pharmaceutical composition comprising the therapeutically effective amount of Eurycoma longifolia extract.

The present invention is directed to a new kind of medicinal value or health care function of Eurycoma longifolia extracts, particularly in the treatment or alleviation symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. In one aspect, the present invention discloses the use of a composition comprising a therapeutically effective amount of Eurycoma longifolia extract in the manufacture of a medicament for the alleviation of symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. The alleviation of the symptoms and/or conditions according to the present invention is characterised by inducing a change in the hormonal contents of estrogen, progesterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Also disclosed is the use of a pharmaceutical composition comprising the therapeutically effective amount of Eurycoma longifolia extract.

Hormone formulations, dosage units including the hormone formulations, and methods of use relate to a controlled release formulation, which includes hormones, e.g., progesterone. Formulations and methods are for controlling the reproductive cycle and/or ovulation of a female mammal, for example, to promote ovulation in a female mammal or synchronizing the ovulation or heat/estrus of a group of female mammals. In addition, formulations are for increasing the likelihood that a female mammal becomes pregnant, for example, after insemination or embryo transference. In addition, formulations are for reducing the anestrous period in a female mammal.

The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.

Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.

The present invention is a compound comprising an anti-inflammatory drug component consisting preferably of at least one of an NSAID portion and a cannabis portion and at least one of a progestin component and a progesterone component. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased riskespecially genetically determined riskof developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.

The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl--cyclodextrin (HPCD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HPCD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.

The invention relates to antibodies directed against follicle-stimulating hormone (FSH) and capable of potentiating the bioactivity of gonadotropins.

Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.